Roche Holding Ag Stock Cash And Equivalents
| RHHBF Stock | USD 302.92 4.06 1.32% |
Roche Holding AG fundamentals help investors to digest information that contributes to Roche Holding's financial success or failures. It also enables traders to predict the movement of Roche OTC Stock. The fundamental analysis module provides a way to measure Roche Holding's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Roche Holding otc stock.
Roche |
Roche Holding AG OTC Stock Cash And Equivalents Analysis
Roche Holding's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Roche Holding Cash And Equivalents | 6.81 B |
Most of Roche Holding's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Roche Holding AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Roche Holding AG has 6.81 B in Cash And Equivalents. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The cash and equivalents for all United States stocks is 152.03% lower than that of the firm.
Roche Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Roche Holding's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Roche Holding could also be used in its relative valuation, which is a method of valuing Roche Holding by comparing valuation metrics of similar companies.Roche Holding is currently under evaluation in cash and equivalents category among its peers.
Roche Fundamentals
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 287.91 B | |||
| Shares Outstanding | 106.69 M | |||
| Shares Owned By Insiders | 75.31 % | |||
| Shares Owned By Institutions | 8.56 % | |||
| Price To Earning | 21.63 X | |||
| Price To Book | 11.61 X | |||
| Price To Sales | 4.11 X | |||
| Revenue | 62.8 B | |||
| Gross Profit | 47.83 B | |||
| EBITDA | 22.26 B | |||
| Net Income | 13.93 B | |||
| Cash And Equivalents | 6.81 B | |||
| Cash Per Share | 8.50 X | |||
| Total Debt | 16.08 B | |||
| Debt To Equity | 1.00 % | |||
| Current Ratio | 1.11 X | |||
| Book Value Per Share | 35.03 X | |||
| Cash Flow From Operations | 20.98 B | |||
| Earnings Per Share | 19.18 X | |||
| Price To Earnings To Growth | 4.18 X | |||
| Target Price | 423.65 | |||
| Number Of Employees | 103.61 K | |||
| Beta | 0.19 | |||
| Market Capitalization | 246.23 B | |||
| Total Asset | 92.32 B | |||
| Retained Earnings | 25.51 B | |||
| Working Capital | 2.16 B | |||
| Current Asset | 26.61 B | |||
| Current Liabilities | 24.46 B | |||
| Z Score | 9.0 | |||
| Annual Yield | 0.03 % | |||
| Five Year Return | 3.23 % | |||
| Net Asset | 92.32 B | |||
| Last Dividend Paid | 9.5 |
About Roche Holding Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Roche Holding AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Roche Holding using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Roche Holding AG based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Roche OTC Stock
Roche Holding financial ratios help investors to determine whether Roche OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Roche with respect to the benefits of owning Roche Holding security.